H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts RAPT Hot Sheet
Price: $58.02 --0%
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Join SI Premium – FREE
H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral with a price target of $58.00.
For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.
Shares of Rapt Therapeutics closed at $35.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Softbank Said To Weigh Buying Largest Us Security Firm Allied - Bloomberg
- Federal Bank Ltd (FB:IN) PT Lowered to INR400 at UBS
- RBC: 'We believe $480/share is a price at which Tesla shareholders should be receptive to a deal'
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
